After Citigroup and Cantor Fitzgerald gave Intercept Pharma (NASDAQ: ICPT) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Mayank Mamtani reiterated a Buy rating on Intercept Pharma today and set a price target of $158.00. The company’s shares closed last Monday at $68.62.
According to TipRanks.com, Mamtani is ranked 0 out of 5 stars with an average return of -9.0% and a 25.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.
Intercept Pharma has an analyst consensus of Strong Buy, with a price target consensus of $151.50, representing a 142.7% upside. In a report issued on March 13, Wedbush also maintained a Buy rating on the stock with a $257.00 price target.
The company has a one-year high of $125.00 and a one-year low of $47.57. Currently, Intercept Pharma has an average volume of 581.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.